Prospective, Single-arm, Phase II Clinical Study of Rituximab, Lenalidomide, and Zanubrutinib Combination Regimen Followed by Immunochemotherapy in the Treatment of Elderly Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Zanubrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Prednisone; Vindesine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 12 Oct 2023 Planned number of patients changed from 48 to 31.
- 13 Dec 2022 Status changed from not yet recruiting to recruiting , according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results (n=26) reporting safety and efficacy data presented at the 64th American Society of Hematology Annual Meeting and Exposition